1. Comprehensive Structure–Activity Relationship of Triantennary N-Acetylgalactosamine Conjugated Antisense Oligonucleotides for Targeted Delivery to Hepatocytes
- Author
-
Sheri L. Booten, W. Brad Wan, Guillermo Vasquez, Susan F. Murray, Audrey Low, Punit P. Seth, Thazha P. Prakash, Heather M. Murray, Alfred E. Chappell, Jeff Crosby, Sebastien A. Burel, Todd Machemer, Armand Soriano, Hans Gaus, Michael T. Migawa, Patrick Cauntay, Jill Hsiao, Jinghua Yu, Mark J. Graham, Recaldo L. Carty, Mariam Aghajan, Michael E. Østergaard, Garth A. Kinberger, Karsten Schmidt, and Eric E. Swayze
- Subjects
Male ,0301 basic medicine ,Tris ,Acetylgalactosamine ,Transgene ,Mice, Transgenic ,Conjugated system ,N-Acetylgalactosamine ,Mice ,Structure-Activity Relationship ,03 medical and health sciences ,chemistry.chemical_compound ,Drug Delivery Systems ,0302 clinical medicine ,Drug Discovery ,Animals ,Humans ,Structure–activity relationship ,Factor XI ,Apolipoprotein C-III ,Mice, Inbred BALB C ,Oligonucleotide ,Oligonucleotides, Antisense ,Scavenger Receptors, Class B ,Molecular biology ,Mice, Inbred C57BL ,carbohydrates (lipids) ,030104 developmental biology ,chemistry ,Biochemistry ,030220 oncology & carcinogenesis ,Hepatocytes ,Molecular Medicine ,lipids (amino acids, peptides, and proteins) ,Conjugate - Abstract
The comprehensive structure-activity relationships of triantennary GalNAc conjugated ASOs for enhancing potency via ASGR mediated delivery to hepatocytes is reported. Seventeen GalNAc clusters were assembled from six distinct scaffolds and attached to ASOs. The resulting ASO conjugates were evaluated in ASGR binding assays, in primary hepatocytes, and in mice. Five structurally distinct GalNAc clusters were chosen for more extensive evaluation using ASOs targeting SRB-1, A1AT, FXI, TTR, and ApoC III mRNAs. GalNAc-ASO conjugates exhibited excellent potencies (ED50 0.5-2 mg/kg) for reducing the targeted mRNAs and proteins. This work culminated in the identification of a simplified tris-based GalNAc cluster (THA-GN3), which can be efficiently assembled using readily available starting materials and conjugated to ASOs using a solution phase conjugation strategy. GalNAc-ASO conjugates thus represent a viable approach for enhancing potency of ASO drugs in the clinic without adding significant complexity or cost to existing protocols for manufacturing oligonucleotide drugs.
- Published
- 2016